Ningetinib (CT053PTSA) Plus Gefitinib in Stage IIIB or IV NSCLC Patients With EGFR Mutation and T790M Negative

• Status: Recruiting
• Trial end date: 2021-11-17
• Target enrollment: 0
• Participant gender: All

Summary

This is a phase Ib, multi-center, open label study evaluating the safety and efficacy of CT053PTSA in combination with gefitinib in patients with EGFR mutation, T790M negative NSCLC who have progressed after EGFR TKI treatment.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sunshine Lake Pharma Co., Ltd.
• Treatments: Gefitinib

Criteria

Inclusion Criteria:

• Histologically or cytologically confirmed Stage IIIB or IV NSCLC

• Resistance to EGFR TKI (1st, 2nd or 3rd generation)

• Histological or cytological evidence of EGFR mutation and T790M negative after progression on last EGFR TKI therapy

• c-Met GCN ≥ 6 or cluster amplification is required if participant is resistant to1st or 2nd generation EGFR-TKI ;c-MET GCN statue is not required, If participant is resistant to3rd generation EGFR-TKI （osimertinib）；

• Measurable disease according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1)

• Toxicity recovered to NCI CTCAE v.4.03 Grade ≤1 from previous treatments (except alopecia)

• ECOG performance status (PS) 0 or 1

• Life expectancy of ≥ 12 weeks

• Adequate organ function

Exclusion Criteria:

• Prior treatments

• Chemotherapy, targeted therapy (except EGFR TKI), immunotherapy, radiotherapy, or major surgery within 4 weeks prior to study treatment

• Nitrosourea and mitomycin chemotherapy within 6 weeks prior to study treatment

• EGFR TKI treatment within 2 weeks prior to study treatment

• Had received live vaccine within 4 weeks prior to study treatment

• Had received any investigational agent from other clinical study within 4 weeks prior to study treatment or are currently participating in other clinical trials

• Previous treatment with any other c-MET inhibitor or Axl inhibitor (eg, crizotinib, cabozantinib, volitinib, INC280)

• Symptomatic, untreated or unstable central nervous system metastases

• Spinal cord compression, carcinomatous meningitis or leptomeningeal diseaseonly (patient are only permitted if treated, asymptomatic and stable for at least 4 weeks prior to start of study treatment)

• Interstitial pneumonia or radiation pneumonitis

• Uncontrolled hypertension that require more than two anti-hypertensive agents to control, or systolic blood pressure (BP) >140mmHg or diastolic BP >90 mmHg before the first administration (BP is the mean blood pressure of two measures that 1 hours interval or above)

• Doppler ultrasound evaluation：Left ventricular ejection fraction < 50%

• Grade ≥ 2 of arrhythmia (assessed by NCI CTCAE 4.03), or symptomatic bradycardia, or male with QTCF > 450 ms or female with QTCF > 470 ms, or patients with a history of torsion or congenital QT prolonged syndrome long QT syndrome

• Certain factors that would preclude adequate absorption of CT053PTSA and gefitinib (eg. unable to swallow, chronic diarrhea, intestinal obstruction)

• Significant hemoptysis within 2 months prior to enrollment, or a daily hemoptysis volume is 2.5 ml or above

• Patients with evidence of bleeding tendency, including the following cases:

gastrointestinal bleeding, hemorrhagic gastric ulcer, fecal occult blood ++ and above; or melena or hematemesis within 2 months; or visceral bleeding that may occur considered by investigator

• History of immunodeficiency, or other acquired or congenital immunodeficiency, or history of organ transplantation

• Any disease of the following bellowed within 12 months prior to administration:

Myocardial infarction, severe angina, or unstable angina, coronary or peripheral artery bypass graft, congestive heart failure, or cerebrovascular events (including transient ischemic attack)

• Pulmonary embolism within 6 months prior to administration

• Active infection of hepatitis B, or infection of HIV

• Other malignancies within 5 years prior to enrollment, with the exception of carcinoma in situ of the cervix, basal or squamous cell skin cancer

• History of thyroid dysfunction, and the thyroid function cannot be maintained at the normal range with drugs.

• Serious electrolyte imbalance in the investigator's judgment

• Pregnant or lactating woman

• Any other reason the investigator considers the patient is not suitable to participate in the study